JAMA

Pair Team Announces the Appointment of Nate Favini, M.D., M.S., as Inaugural Chief Medical Officer

Retrieved on: 
Thursday, February 1, 2024
Health, SAN, JAMA, Population health, Growth, Senior, Nate, CareMore, Federally Qualified Health Center, Patient, Safety, UCLA, American Medical Association, Public health, Harvard Medical School, Forward, Social support, Journal, Connie, American Journal, Management

SAN FRANCISCO, Feb. 1, 2024 /PRNewswire/ -- Pair Team, a virtual and community-based care solution connecting Medicaid's highest-risk patients to high-quality care, today announced the appointment of its first-ever Chief Medical Officer, Nate Favini, M.D., M.S. In this role, Nate will oversee clinical services at Pair Team, including supporting and scaling its clinical teams, leading population health efforts, shaping the company's value-based care strategy and developing new clinical programs and services to improve the health of its patients and lower total costs of care.

Key Points: 
  • We're poised for another year of explosive growth and hiring Nate enables us to do so," said Neil Batlivala, co-founder and CEO of Pair Team.
  • Nate joins Pair Team from Forward, where he served as Chief Medical Officer.
  • In addition to Nate's new role as Chief Medical Officer, Pair Team has also announced two new appointments within its leadership team:
    Connie Kim , Executive Vice President of Operations.
  • For more information about Pair Team or if you're interested in joining its team, please visit www.pairteam.com .

CDC Foundation's Live to the Beat campaign spotlights cardiovascular disease in Black women, issuing a call-to-action to help Black women prioritize self-care for their own heart health

Retrieved on: 
Thursday, February 1, 2024
Steps, Anxiety, CVD, JAMA, Research, Health equity, Cardiovascular disease, News, House, American Medical Association, Moyamoya disease, Friends, Beat, American Heart Month, CDC, Depression, Social media, Health education, Challenge, Risk, Journal, Cancer, EST, Stroke, Health, White, Woman

Black women are bearing the brunt of the toll cardiovascular disease (CVD) is having on women in the United States.

Key Points: 
  • Black women are bearing the brunt of the toll cardiovascular disease (CVD) is having on women in the United States.
  • CDC Foundation's Live to the Beat campaign is launching a "Heart2Heart Challenge" to encourage Black women to give themselves permission to prioritize self-care for their own heart health.
  • "Black women are the figurative heartbeats of Black families and communities, but many of their own hearts are in trouble.
  • Now entering its third year, the CDC Foundation's Live to the Beat campaign is CDC's first national cardiovascular disease prevention campaign developed for the Black community.

Waystar Partners with MEDITECH to Accelerate Mission of Simplifying Healthcare Payments

Retrieved on: 
Thursday, February 1, 2024
Partnership, Expanse, EHR, JAMA, Patient, Friction, American Medical Association, MEDITECH, Journal, Organization, Health, Sales

LEHI, Utah and LOUISVILLE, Ky., Feb. 1, 2024 /PRNewswire/ -- Waystar Technologies, Inc., a provider of leading healthcare payment technology, today announced a new partnership with MEDITECH, a leading global electronic health record (EHR) provider. Through the partnership, healthcare organizations currently working with MEDITECH will have the ability to leverage Waystar's award-winning platform, empowering those providers to remove friction from their financial operations and focus on delivering high-quality care to patients.

Key Points: 
  • As administrative expenses increasingly weigh on the U.S. healthcare system, partnerships like Waystar and MEDITECH are essential to reducing the burden on providers and patients.
  • Matt Hawkins, Chief Executive Officer of Waystar, said, "Waystar and MEDITECH share a commitment to transforming the healthcare landscape through digital innovation.
  • This partnership immediately expands the reach of our platform, furthering our mission of simplifying healthcare payments.
  • "MEDITECH is pleased to welcome Waystar into our Alliance program to provide clients with another integrated solution," said MEDITECH Chief Business Development Officer Jim Merlin.

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024

Retrieved on: 
Wednesday, January 24, 2024
DAN, Woman, ResMed, Patient, Wind, Software as a service, Magnet, American Medical Association, COPD, JAMA, Investment, CDI, Journal, Acquisition, Chronic obstructive pulmonary disease, Webcast, Retirement, Australian Securities Exchange, CHESS, Mask, Growth

SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2023.

Key Points: 
  • Gross margin decreased by 50 basis points mainly due to costs associated with a field safety notification for masks with magnets.
  • SG&A expenses improved to 19.1 percent of revenue in the quarter, compared with 20.5 percent in the same period of the prior year.
  • ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from February 7, 2024, through February 8, 2024, inclusive.
  • ResMed will discuss its second quarter fiscal year 2024 results on its webcast at 1:30 p.m. U.S. Pacific Time today.

Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, January 18, 2024
Patient, EFS, ASCO, Diagnosis, Trial of the century, Society, American Medical Association, Lung cancer, NSCLC, Shanghai Chest Hospital, JAMA, Journal, Safety, Shanghai Jiao Tong University, Medical device

NEOTORCH is a randomized, double-blind, placebo-controlled phase 3 trial evaluating the efficacy and safety of toripalimab in combination with perioperative platinum-based chemotherapy vs chemotherapy alone in patients with resectable stage II or III NSCLC.

Key Points: 
  • NEOTORCH is a randomized, double-blind, placebo-controlled phase 3 trial evaluating the efficacy and safety of toripalimab in combination with perioperative platinum-based chemotherapy vs chemotherapy alone in patients with resectable stage II or III NSCLC.
  • NEOTORCH is the world’s first phase III clinical study of a anti-PD-1 monoclonal antibody for NSCLC perioperative treatment (including neoadjuvant and adjuvant) with positive EFS results.
  • As a phase 3 clinical study of perioperative treatment, NEOTORCH enrolled the largest sample of resectable stage III NSCLC patients in China.
  • We anticipate that toripalimab will guide China’s perioperative lung cancer treatment into a new era.

New Study Published in JAMA Neurology Affirms High Diagnostic Accuracy of ALZpath's pTau217 Test in Identifying Amyloid and Tau in the Brain

Retrieved on: 
Monday, January 22, 2024
Cerebrospinal fluid, Classification, Pathology, Research, Diagnosis, CSF, Neuro, PET, Immunoassay, University, Amyloid, JAMA, Plasma, AUC, Biomarker, Neurology, Single, Brain, Test management, Blood, Medical imaging

CARLSBAD, Calif., Jan. 22, 2024 /PRNewswire/ -- ALZpath, Inc. (ALZpath), a leader in Alzheimer's diagnostics, announced new findings published online today in JAMA Neurology showing that its proprietary blood-based biomarker assay for phosphorylated tau at residue 217 (pTau217) delivers high diagnostic accuracy and consistency in identifying amyloid and tau in the brain. The article, "Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer's Disease Pathology," was authored by Dr. Nicholas Ashton and colleagues from the University of Gothenburg, Sweden.

Key Points: 
  • With the novel ALZpath pTau217 assay and test, ALZpath is transforming Alzheimer's disease diagnosis and monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide.
  • The ALZpath pTau217 assay showed high diagnostic accuracy in identifying elevated amyloid (AUC, 0.92-0.96; 95%CI 0.89-0.99) and tau (AUC, 0.93-0.97; 95%CI 0.84-0.99) in the brain across all cohorts.
  • Longitudinally, ALZpath's pTau217 test in blood showed an annual increase in individuals with amyloid plaques, with the highest increase observed in those who also had tau pathology.
  • The ALZpath pTau217 test will also be commercially available on other research and diagnostic platforms in support of global accessibility and scalability.

Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences’ Patent

Retrieved on: 
Friday, January 12, 2024
Legal, Biotechnology, Oncology, General Health, Health, Medical Devices, Professional Services, Other Health, Blood, Mortality, Patient, Cohort (statistics), Incidence, RNA, Cancer, American Medical Association, District court, JAMA, Journal, FDA, Dicarboxylic acid, Patent, CRC, Colorectal cancer, Motion, Exact sciences, AA, Trial of the century

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that it has petitioned the United States Patent and Trademark Office (USPTO) for inter partes review challenging the patentability of United States Patent No.

Key Points: 
  • Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that it has petitioned the United States Patent and Trademark Office (USPTO) for inter partes review challenging the patentability of United States Patent No.
  • 11,634,781 (“the ’781 patent”) owned by Exact Sciences.
  • The fecal tests for detecting blood protein and nucleic acids recited by the claims were known and routine.
  • The claimed method of the ’781 patent is obvious, and the claims directed to the method are invalid.

Trifecta: A Leading Force in Organic Meal Delivery, Takes Center Stage in Netflix Documentary

Retrieved on: 
Thursday, January 4, 2024
Garder, Economic development, Oceanic, Stanford University, Entrepreneurship, Academy Awards, Research, Apolipoprotein, Diet, Health, Insulin, DNA, Twin, Trifecta, Netflix, Food, JAMA, OPS, Human, Environment, Dietary supplement

The documentary, “You Are What You Eat: A Twin Experiment” sheds light on the critical importance of mindful eating and the impact of diet on our bodies.

Key Points: 
  • The documentary, “You Are What You Eat: A Twin Experiment” sheds light on the critical importance of mindful eating and the impact of diet on our bodies.
  • Produced by Academy Award-winning Director Luis Psihoyos, the series delves into a groundbreaking diet study conducted by Stanford Professor Dr. Christopher Gardner featured in JAMA .
  • The research involved twins following different diets: one consumed an omnivorous diet, while the other adopted a vegan diet.
  • As Trifecta continues to redefine the meal delivery landscape, this documentary serves as a powerful reminder of the impact our food choices have on our well-being and the environment.

AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial

Retrieved on: 
Friday, December 15, 2023
Partnership, AC, Deficit spending, Johnson & Johnson, Janssen Pharmaceuticals, Function (mathematics), Biomarker, FDA, Janssen, Injection, Biologics license application, Clinical trial, CHF, Dementia, JAMA, Pathology, Neurotoxicity, Patient, MCI, Memory, Tauopathy, BLA, Vaccine

ACI-35.030 is an investigational targeted active immunotherapy, selective for pathological phosphorylated Tau (pTau).

Key Points: 
  • ACI-35.030 is an investigational targeted active immunotherapy, selective for pathological phosphorylated Tau (pTau).
  • Studies have shown that pTau correlates with AD progression and the trial aims to show that ACI-35.030 can prevent or slow down the progression of tau pathology and onset of clinical symptoms.
  • The partnership with Janssen aims to develop and commercialize therapeutic anti-Tau active immunotherapies for the treatment of AD and potentially other Tauopathies.
  • It is sensitive enough to detect early changes in cognitive function, even before the first clinical signs of mild cognitive impairment (MCI) are apparent2.

Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally

Retrieved on: 
Thursday, December 7, 2023
Urinary tract infection, JAMA, ASX, Risk, Woman, COPD, Prevalence, Disease, Lung cancer, SAN, RMD, Education, Gestational sac, Low, Air pollution, Emphysema, Chronic obstructive pulmonary disease, American Medical Association, JAMA Network Open, Tobacco smoking, World Health Organization, ResMed, Growth, Patient, Bronchitis, Journal, Female, Dust, Pharmaceutical industry

According to the World Health Organization , COPD is the third deadliest disease in the world.

Key Points: 
  • According to the World Health Organization , COPD is the third deadliest disease in the world.
  • Today, there are an estimated 480 million people who suffer from COPD.
  • This study in JAMA Network Open projects the increased regional and global burden of COPD by 2050 through an analysis of historical COPD prevalence and data on COPD risk factors such as tobacco smoking, outdoor air pollution, and household air pollution.
  • “The disproportionate growth of COPD among women is a critical finding as COPD has not always been as prevalent in women.